Natural History of Vanishing White Matter
Ann Neurol; 84(2):274-288. doi: 10.1002/ana.25287. Epub 2018 Sep 6. PMID: 30014503; PMCID: PMC6175238.
Cell Replacement Therapy Improves Pathological Hallmarks in a Mouse Model of Leukodystrophy Vanishing White Matter
Stem Cell Reports; 12(3):441-450. doi: 10.1016/j.stemcr.2019.01.018. Epub 2019 Feb 21. PMID: 30799272; PMCID: PMC6411482.
Bergmann glia translocation: a new disease marker for vanishing white matter identifies therapeutic effects of Guanabenz treatment
Neuropathol Appl Neurobiol; 44(4):391-403. doi: 10.1111/nan.12411. Epub 2017 Aug 1. PMID: 28953319.
eIF2B activator prevents neurological defects caused by a chronic integrated stress response
8:e42940. doi: 10.7554/eLife.42940. PMID: 30624206; PMCID: PMC6326728.
The small molecule ISRIB rescues the stability and activity of Vanishing White Matter Disease eIF2B mutant complexes
7:e32733. doi: 10.7554/eLife.32733. PMID: 29489452; PMCID: PMC5829914.
Drug Screening Identifies Sigma-1-Receptor as a Target for the Therapy of VWM Leukodystrophy
Front Mol Neurosci. 2018;11:336. Published 2018 Sep 18. doi:10.3389/fnmol.2018.00336
Vanishing white matter: deregulated integrated stress response as therapy target
Ann Clin Transl Neurol. 2019 Aug;6(8):1407-1422. doi: 10.1002/acn3.50826. Epub 2019 Jul 18. PMID: 31402619; PMCID: PMC6689685.
Identification of repurposable cytoprotective drugs in vanishing white matter disease patient-derived cells
transl med commun 5, 18 (2020). https://doi.org/10.1186/s41231-020-00071-0
Vanishing white matter: a leukodystrophy due to astrocytic dysfunction
Brain Pathol. 2018 May;28(3):408-421. doi: 10.1111/bpa.12606. PMID: 29740943.
Vanishing white matter disease
Lancet Neurol. 2006 May;5(5):413-23. doi: 10.1016/S1474-4422(06)70440-9. PMID: 16632312.